Léim chuig an ábhar
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Teanga
Gach réimse
Teideal
Údar
Ábhar
Gairmuimhir
ISBN/ISSN
Clib
AIMSIGH
CASTA
Statin Cost-Effectiveness in t...
Luaigh é seo
Seol mar théacs é seo
Seol é seo mar r-phost
Priontáil
Easpórtáil taifead
Easpórtáil chuig RefWorks
Easpórtáil chuig EndNoteWeb
Easpórtáil chuig EndNote
Buan-nasc
Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:
Mihaylova, B
,
Briggs, A
,
Hlatky, M
,
Armitage, J
,
Parish, S
,
Gray, A
,
Collins, R
,
Study, HP
Formáid:
Journal article
Foilsithe / Cruthaithe:
2009
Stoc
Cur síos
Míreanna comhchosúla
Amharc foirne
Cur síos
Achoimre:
Míreanna comhchosúla
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
de réir: Mihaylova, B, et al.
Foilsithe / Cruthaithe: (2005)
Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
de réir: Mihaylova, B, et al.
Foilsithe / Cruthaithe: (2005)
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
de réir: Mihaylova, B, et al.
Foilsithe / Cruthaithe: (2006)
Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study
de réir: Mihaylova, B, et al.
Foilsithe / Cruthaithe: (2024)
The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
de réir: Kent, S, et al.
Foilsithe / Cruthaithe: (2016)